Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin

Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy

In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.

To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA isolation kit, and SNP polymorphisms will be evaluated.

Inclusion Criteria:

• aged 18 or older
• curatively resected colon adenocarcinoma
• pathologically staged III
• adequate performance status
• adequate major organ functions
• to be treated with adjuvant FOLFOX chemotherapy
• written informed consent

Exclusion Criteria:

• those who disagree the study